Low Weight Heparin prOphylaxis for Placental-Mediated Complications of PrEgnancy
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is a Multicenter, randomized, open-label, parallel groups study to test the hypothesis
that prophylactic low molecular weight heparin (LMWH) (enoxaparin) initiated before 14 weeks
of gestation could improve maternal and perinatal outcome in women at high risk for
developing placental-mediated pregnancy complications.
Phase:
Phase 3
Details
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute
Collaborators:
Hospital de Cruces Hospital Sant Joan de Deu Hospital Vall d'Hebron Parc Sanitari Sant Joan de Déu